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ABSTRACT
Background. Many women at increased risk for breast
cancer could benefit from preventive therapy. Preventive
therapy options for breast cancer risk reduction have
expanded in the last few years to include both selective
receptor modulators (tamoxifen and raloxifene) and aro-
matase inhibitors (anastrozole and exemestane).
Methods. Risk factors that place women at high risk for
breast cancer, as well as risk calculation models appro-
priate for the selection of candidates for preventive
therapy, are presented, followed by a review of current
guidelines for chemoprevention and results of chemopre-
vention trials.
Results. The modified Gail model or Breast Cancer
Risk Assessment Tool is the most widely utilized risk
assessment calculator to determine eligibility for chemo-
prevention. Women most likely to benefit from preventive
therapy include those at high risk under the age of 50 years
and those with atypical hyperplasia. Physician and patient
barriers limit widespread acceptance and adherence to
preventive therapy.
Conclusions. Published guidelines on chemoprevention
for breast cancer have been updated to increase awareness
and encourage discussion between patients and their
physicians regarding evidence-based studies evaluating the
benefits of preventive options for women at increased risk
for breast cancer. However, even with increasing aware-
ness and established benefits of preventive therapy, the
uptake of chemoprevention has been low, with both
physician and patient barriers identified. It is prudent that
these barriers be overcome to enable high-risk women with
a favorable risk-to-benefit ratio to be offered chemopre-
vention to reduce their likelihood of developing hormone
receptor-positive breast cancer.
DEFINING BREAST CANCER RISK
Defining breast cancer risk incorporates knowledge of
individual risk factors known to be associated with
increased risk. These risk factors are included in various
available risk-calculation models to provide a numeric risk
that can be used to help quantify the level of individual
risk.1
Breast cancer risk factors have historically been
described as modifiable versus nonmodifiable factors.
Modifiable risk factors in general are associated with life-
style behaviors and exogenous hormone exposure. These
include physical inactivity, increased alcohol consumption,
obesity, and use of estrogen and progestin therapies, all of
which are associated with increasing breast cancer risk.2–5
Physicians have an important role in counseling women on
the effectiveness of lifestyle modification and avoidance of
long-term postmenopausal hormone therapy in the primary
prevention of breast cancer. Nonmodifiable risk factors
include increasing age, family history, precancerous breast
lesions, and reproductive factors (early menarche, late-
onset menopause, first live birth after age 30 years, or
nulliparity). These risk factors are independently associated
with a higher risk of developing breast cancer but it is not
known if they are additive for an individual when esti-
mating breast cancer risk.
Breast cancer risk can be categorized as average, high,
and very high risk.6 In general, a woman having no family
history of breast cancer or prior history of a precancerous
breast biopsy would be considered at average risk. The
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lifetime risk for developing breast cancer for an average-
risk woman is 12 %. The following criteria are most often
used to identify women at high risk: (i) first-degree relative
with a breast cancer diagnosis before age 50 years; (ii)
history of atypical hyperplasia (AH); (iii) 5-year Gail
model risk of C1.7 %; (iv) history of lobular carcinoma
in situ (LCIS); (v) having received chest radiation between
the ages of 10 and 30 years; (vi) increased mammographic
breast density; and (vii) International Breast Cancer Inter-
vention Study (IBIS) model (Tyrer–Cuzick) lifetime risk of
C20 %.7–12 Breast cancer risk factors and the respective
absolute or attributable risk of developing breast cancer are
described in Table 1.
Women presenting with a strong hereditary predisposi-
tion, or known BRCA1 or 2 mutation carriers, are, by
definition, considered at very high risk for developing
breast cancer. A family history that entails multiple
affected relatives with early-onset breast or ovarian cancer
over several generations would be an indication to refer to
a genetic counselor to discuss the options of genetic test-
ing. The lifetime risk of developing invasive breast cancer
for a BRCA mutation carrier is estimated at 40–85 %.13
Women with a BRCA mutation should be offered bilateral
prophylactic mastectomy (BPM) and risk-reducing salp-
ingo-oophorectomy as these are the only risk-reducing
strategies shown to be effective in this population. Those
not interested in BPM should have enhanced surveillance
with annual mammogram and magnetic resonance imag-
ing, and be offered preventive therapy. The evidence of
efficacy of preventive therapy in this population is less
compelling.14,15 Although there is no evidence to support
BPM in women who have had thoracic radiation, there is
preclinical evidence that tamoxifen decreases the incidence
of radiation-induced breast cancer.16,17
Several complementary risk assessment and calculation
tools are available to assist physicians with making deci-
sions regarding preventive therapy, and individualizing
risks. These tools incorporate most of the breast cancer risk
factors described above and are easily available to the
physician at the point of care. When counseling women
about preventive therapy, it is recommended that physi-
cians use a shared decision-making approach with women
at high or very high risk as they are most likely to benefit
from risk-reduction options.18,19 Women with a history of
prior chest-wall radiation age\30 years, or women with a
history of LCIS, are considered to be high enough risk to be
considered for preventive therapy [National Comprehen-
sive Cancer Network (NCCN) guidelines version 1.2014
Breast Cancer Risk Reduction]. Other women can be
assessed for suitability by using a risk assessment tool.
DETERMINING ELIGIBILITY FOR PREVENTIVE
THERAPY/RISK ASSESSMENT TOOLS
The American Society of Clinical Oncology, the NCCN,
the Canadian Task Force on Preventive Health Care, and the
US Preventive Services Task Force (USPSTF) advise
counseling women C35 years of age who are at increased
risk for breast cancer regarding available medications to
reduce their risk and to offer medication to women at low risk
of medication-related side effects (USPSTF B recommen-
dation).20–23 The Gail model risk calculator is the most
widely utilized tool to identify candidates suitable for
chemoprevention.9,24–26 The original validated Gail model
was updated and modified to become the Breast Cancer Risk
Assessment Tool (BCRAT) by the National Cancer Institute
and the National Surgical Adjuvant Breast and Bowel Pro-
ject (NSABP) Biostatistics Center.27 The BCRAT includes
the following breast cancer risk factors: current age, repro-
ductive history (age at menarche, age at first live birth),
history of prior breast disease (number of previous breast
biopsies and history of AH), and family history (number of
first-degree relatives with breast cancer), with age being the
most heavily weighted risk factor.27
This model does not include the age of onset of breast
cancer in family members, paternal family history, or any
family history of ovarian cancer. It is suitable for women
C35 years of age with no history of ductal carcinoma
in situ (DCIS) or LCIS, no prior history of thoracic radi-
ation, and without a strong family history of breast cancer
or ovarian cancer suggestive of a genetic predisposition.
The model was updated in 2008 to provide adjusted esti-
mates for African American women derived from the
TABLE 1 Definition of high risk
Risk factor Defining high risk
First-degree family member
diagnosed at\50 years of
age
Twofold risk
Atypical hyperplasia Cumulative absolute risk is 30 %
at 25-year follow-up
Chest radiation between 10 and
30 years of age
40 % lifetime risk
Gail model 5-year risk Five-year risk C1.7 %
Breast density (BI-RADS, D3 or
D4)
Women with extremely dense
breasts have a twofold
increased risk compared with
average women





C20 % lifetime risk
BI-RADS Breast Imaging Reporting and Data System, D3 the breast
tissue is heterogeneously dense, D4 the breast tissue is extremely
dense
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Women’s Contraceptive and Reproductive Experiences
(CARE) Study and from Surveillance, Epidemiology and
End Results (SEER) data, and in 2011 to include Asian and
Pacific Islander women using data from the Asian Ameri-
can Breast Cancer Study (AABCS) combined with the
SEER database.25,28
Any woman with a 5-year risk of C1.7 % determined by
using the Gail model can be considered for preventive
therapy. This is the risk estimate utilized for the major
breast cancer prevention trials and supported by NCCN
guidelines.21 Based on risk–benefit tables developed by
Freedman et al.29 the USPSTF concludes that, in general,
women with an estimated 5-year breast cancer risk of
C3 % are likely to have more benefit than harm from using
a selective estrogen receptor modulator (SERM) as
chemoprevention, although the balance depends on age,
ethnicity, the medication used, and whether or not the
patient has a uterus.23
In general, women with a history of AH, or women
under the age of 50 years, are more likely to benefit from
preventive therapy. This is based on the Breast Cancer
Prevention Trial (BCPT) data subgroup analysis that
demonstrated a significant 86 % risk reduction for women
with AH. Furthermore, the evidence supports that women
under the age of 50 years are far less likely to incur the
harms of therapy seen in women 50 years of age or
older.30,31 Conversely, in many older women the harms of
preventive therapy far outweigh the benefits as their risk of
adverse effects is greater.
The NCCN Breast Cancer Risk Reduction Panel has
adopted the 1.7 % or greater 5-year actuarial breast cancer
risk defined by the modified Gail model as the risk threshold
for discussion of chemoprevention. This is consistent with
eligibility criteria utilized in the NSABP BCPT and the
Study of Tamoxifen and Raloxifene (STAR).30–33Another
risk calculation model commonly used is the IBIS or Tyrer–
Cuzick model.11 It includes BRCA status, height, weight,
hormone replacement therapy (HRT) use, age at first live
birth, age of onset of cancers in relatives, the presence of
ovarian cancer, and second- and third-generation family
history on the maternal and paternal side. It is more complex,
less accessible to primary care providers, and currently uti-
lized mainly to determine eligibility for enhanced screening
with MRI, in addition to mammography, in women with a
lifetime risk of breast cancer C20 %.
The recently updated American Society of Clinical
Oncology guideline on the use of pharmacological inter-
ventions for breast cancer risk reduction states that the risk
for breast cancer may be determined by the aforementioned
BCRAT tool ‘‘or other validated models including Tyrer–
Cuzick’’.20
In a head-to-head comparison of the BCRAT and the IBIS
model looking at the absolute 10-year risk of breast cancer,
the IBIS model showed better discrimination (area under the
curve [AUC] for IBIS 69.5 %, 95 % CI 63.8–75.2 versus
AUC for BRCAT 63.2 %, 95 % CI 57.6–68.9).34
There is no validated model that accounts for breast
density, yet it is hoped that one might be developed in the
future that will include breast density and be capable of
effectively identifying women suitable for both enhanced
screening and chemoprevention.35
PREVENTIVE THERAPY
Tamoxifen and raloxifene, both SERMs, as well as two
aromatase inhibitors (AIs), exemestane and anastrozole,
have been shown in randomized controlled trials to sig-
nificantly reduce breast cancer incidence in women at
increased risk of the disease.30–33,36,37 The SERMs are US
FDA approved for this indication in postmenopausal
women, although only tamoxifen has been studied and
received an indication for breast cancer risk reduction in
premenopausal women. The FDA has not approved either
of these two AIs for breast cancer risk reduction, and their
use in the US is considered off-label. There are a paucity of
data on the effectiveness of preventive therapy in women
with a history of chest-wall radiation.38
Tamoxifen and Raloxifene
In the landmark BCPT, tamoxifen reduced the risk of
breast cancer in both pre- and postmenopausal women at
increased risk of the disease by approximately one-half
(relative risk [RR] 0.51; 95 % CI 0.39–0.66). Women with
AH had a highly significant 86 % breast cancer risk
reduction (RR 0.14; 95 % CI 0.03–0.47), whereas women
with LCIS, due to the small sample size, had a nonstatis-
tically significant reduction of 56 % (RR 0.44; 95 % CI
0.16–1.06).30 Women under the age of 50 years obtained
comparable breast cancer risk reduction to women 50 years
of age and older. In the 7-year follow-up analysis, the
benefits of tamoxifen were shown to persist in women at
increased risk of the disease, even after stopping therapy,
with a reduction in breast cancer risk of 43 % (RR 0.57;
95 % CI 0.46–0.70). Risk remained decreased by 75 %
(RR 0.25; 95 % CI 0.10–0.52) in women with AH, while
women with LCIS continued to have a nonstatistically
significant risk reduction, now 46 % (RR 0.54; 95 % CI
0.27–1.02).31 An updated analysis of the European IBIS-I
trial has demonstrated that tamoxifen continues to reduce
breast cancer risk at a median of 16 years of follow-up (HR
0.71; 95 % CI 0.60–0.83). The risk of developing breast
cancer was similar between years 0–10 (HR 0.72; 95 % CI
0.59–0.88) and after 10 years (HR 0.69; 95 % CI
0.53–0.91).14
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Tamoxifen is associated with an increased risk of
endometrial cancer (RR 2.53; 95 % CI 1.35–4.97; absolute
annual risk per 1000: placebo 0.91 vs. tamoxifen 2.30),
venous thromboembolic events, including stroke (RR 1.59;
95 % CI 0.93–2.77; absolute annual risk per 1000: placebo
0.92 vs. tamoxifen 1.45), pulmonary embolus (RR 3.01;
95 % CI 1.15–9.27; absolute annual risk per 1000: placebo
0.23 vs. tamoxifen 0.69), deep vein thrombosis (RR 1.60;
95 % CI 0.91–2.86; absolute annual risk per 1000: placebo
0.84 vs. tamoxifen 1.34), cataract development (RR 1.14;
95 % CI 1.01–1.29; absolute annual risk per 1000: placebo
21.72 vs. tamoxifen 24.82), and the need for cataract
surgeries (RR 1.57; 95 % CI 1.16–2.14; absolute annual
risk per 1000: placebo 3.00 vs. tamoxifen 4.72).30 These
risks were not significantly different in the 2010 analysis.
The serious risks were not significantly increased in women
under the age of 50 years, thus identifying a population of
women who obtain significant risk reduction benefits
without incurring serious harm. Common side effects
reported included bothersome hot flashes and vaginal
discharge.
The STAR demonstrated that raloxifene was equivalent
to tamoxifen in reducing breast cancer risk for post-
menopausal women at increased risk of the disease while
on therapy.32 In the 2010 updated analysis, with a median
follow-up of 81 months, benefits with tamoxifen were
greater, while the risks were lower with raloxifene.
Raloxifene retained 76 % of the effectiveness of tamoxifen
in preventing invasive disease. Raloxifene was not asso-
ciated with an increased risk of uterine cancer risk and has
a slightly lower risk of venous thromboembolic events than
tamoxifen.33 Raloxifene is associated with hot flashes,
night sweats, vaginal dryness, and weight gain.
Aromatase Inhibitors
In the National Cancer Institute of Canada (NCIC)
Mammary Prevention 3 (MAP.3) trial, after 35 months of
follow-up, exemestane reduced breast cancer risk by 65 %
(hazard ratio [HR] 0.35; 95 % CI 0.18–0.70) in high-risk
postmenopausal women.36 A 53 % reduction in breast
cancer risk was seen with anastrozole in the European
IBIS-II trial in women at increased risk of breast cancer
(HR 0.47; 95 % CI 0.32–0.68).37 Data on AIs in women
with AH or LCIS are limited. In this subgroup, anastrozole
reduced breast cancer risk by 69 % (HR 0.31; 95 % CI
0.12–0.84),37 whereas exemestane produced a nonsignifi-
cant reduction in the risk of breast cancer by 64 % (HR
0.36; 95 % CI 0.11–1.12).36 It is important to note that
these analyses are in a very small number of women,
limiting the ability to assess the effectiveness of therapies
in women with LCIS or AH.
Neither exemestane nor anastrozole were associated with
an increased risk of thromboembolic or cardiovascular
events, or other cancers. In the MAP.3 trial, although short-
term use of exemestane was shown to worsen age-related
bone loss in spite of calcium and vitamin D supplementa-
tion, long-term follow-up will be needed to assess the effect
on fracture risk in a prevention population.39 The side
effects of exemestane, including vasomotor, sexual, and
musculoskeletal symptoms, had limited impact on quality of
life.40 In addition to vasomotor symptoms, musculoskeletal
events (arthralgias, joint stiffness, carpal tunnel syndrome)
were more common in the anastrozole arm.37
Although it is important that high-risk women be con-
sidered for chemoprevention, several barriers have been
identified that impact uptake, compliance, and adherence.
These include fear of possible side effects of the anti-
estrogen therapies, specifically thromboembolic events and
an endometrial cancer risk, which may be perceived as
outweighing the potential benefits of the pharmacologic
therapy on reducing the incidence of breast cancer.41–44
Furthermore, it is becoming increasingly evident that
physicians are encountering barriers to prescribing phar-
macologic therapies, including lack of time to effectively
counsel patients about available options, knowledge gaps
about the risks and benefits of the medications, and chal-
lenges with identifying eligible women with a favorable
risk-to-benefit ratio who will benefit from the pharmaco-
logic therapy to reduce breast cancer risk.45,46
CONCLUSIONS
Physicians are strongly encouraged to assess breast
cancer risk and appropriately identify high-risk women
with a positive risk–benefit ratio eligible for chemopre-
vention. Communication of the risks and benefits of
SERMs and AIs as preventive therapies and shared deci-
sion-making approaches are critical to patient uptake and
adherence. More widespread utilization of these agents can
reduce the incidence of estrogen receptor (ER)-positive
breast cancer but will have no impact on ER-negative
breast cancer. Future opportunities for breast cancer risk
reduction should target hormone-negative, especially tri-
ple-negative, breast cancer.
DISCLOSURE Sandhya Pruthi, Ruth E. Heisey, and Therese B.
Bevers declare they have nothing to disclose.
OPEN ACCESS This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
Chemoprevention for Breast Cancer 3233
REFERENCES
1. Cummings SR, Tice JA, Bauer S, et al. Prevention of breast
cancer in postmenopausal women: approaches to estimating and
reducing risk. J Natl Cancer Inst. 2009;101:384–98.
2. Key J, Hodgson S, Omar RZ, et al. Meta-analysis of studies of
alcohol and breast cancer with consideration of the method-
ological issues. Cancer Causes Control. 2006;17:759–70.
3. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE.
Adult weight change and risk of postmenopausal breast cancer.
JAMA. 2006;296:193–201.
4. Lahmann PH, Friedenreich C, Schuit AJ, et al. Physical activity
and breast cancer risk: the European Prospective Investigation
into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev.
2007;16:36–42.
5. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE.
Endogenous estrogen, androgen, and progesterone concentrations
and breast cancer risk among postmenopausal women. J Natl
Cancer Inst. 2004;96:1856–65.
6. Pruthi S, Heisey R, Bevers T. Personalized assessment and
management of women at risk for breast cancer in North
America. Womens Health (Lond Engl). 2015;11:213–24.
7. Hartmann LC, Degnim AC, Santen RJ, Dupont WD, Ghosh K.
Atypical hyperplasia of the breast–risk assessment and manage-
ment options. N Engl J Med. 2015;372:78–89.
8. Clemons M, Loijens L, Goss P. Breast cancer risk following irra-
diation for Hodgkin’s disease.Cancer Treat Rev. 2000;26:291–302.
9. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized
probabilities of developing breast cancer for white females who
are being examined annually. J Natl Cancer Inst. 1989;81:
1879–86.
10. Page DL, Kidd TE Jr, Dupont WD, Simpson JF, Rogers LW.
Lobular neoplasia of the breast: higher risk for subsequent
invasive cancer predicted by more extensive disease. Hum
Pathol. 1991;22:1232–9.
11. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model
incorporating familial and personal risk factors [published erra-
tum appears in Stat Med. 2005;24(1):156]. Stat Med. 2004;23:
1111–30.
12. Freer PE. Mammographic breast density: impact on breast cancer risk
and implications for screening. Radiographics. 2015;35:302–15.
13. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2
penetrance. J Clin Oncol. 2007;25:1329–33.
14. Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention
of breast cancer: extended long-term follow-up of the IBIS-I
breast cancer prevention trial. Lancet Oncol. 2015;16:67–75.
15. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer
incidence among women with inherited mutations in BRCA1 and
BRCA2: National Surgical Adjuvant Breast and Bowel Project
(NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;286:
2251–6.
16. Peterson NC, Servinsky MD, Christian A, et al. Tamoxifen
resistance and Her2/neu expression in an aged, irradiated rat
breast carcinoma model. Carcinogenesis. 2005;26:1542–52.
17. Boucher AA, Blaes AH. Prophylactic mastectomy: a treatment
alternative for Hodgkin survivors? Clin Breast Cancer. 2013;13:
307–8.
18. Ropka ME, Keim J, Philbrick JT. Patient decisions about breast
cancer chemoprevention: a systematic review and meta-analysis.
J Clin Oncol. 2010;28:3090–5.
19. Ozanne EM, Wittenberg E, Garber JE, Weeks JC. Breast cancer
prevention: patient decision making and risk communication in
the high risk setting. Breast J. 2010;16:38–47.
20. Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic
interventions for breast cancer risk reduction: American Society
of Clinical Oncology clinical practice guideline. J Clin Oncol.
2013;31:2942–62.
21. National Comprehensive Cancer Network. (2014). The NCCN
Clinical Practice Guidelines in Oncology (NCCN Guidelines)
Breast Cancer Risk Reduction (version 1.2014). www.NCCN.org.
Accessed 24 Mar 2015.
22. Levine M, Moutquin JM, Walton R, Feightner J. Chemoprevention
of breast cancer. A joint guideline from the Canadian Task Force on
Preventive Health Care and the Canadian Breast Cancer Initiative’s
Steering Committee on Clinical Practice Guidelines for the Care and
Treatment of Breast Cancer. CMAJ. 2001;164:1681–90.
23. Moyer VA. Medications to decrease the risk for breast cancer in
women: recommendations from the U.S. Preventive Services
Task Force recommendation statement. Ann Intern Med.
2013;159:698–708.
24. Costantino JP, Gail MH, Pee D, et al. Validation studies for
models projecting the risk of invasive and total breast cancer
incidence. J Natl Cancer Inst. 1999;91:1541–8.
25. Gail MH, Costantino JP, Pee D, et al. Projecting individualized
absolute invasive breast cancer risk in African American women.
J Natl Cancer Inst. 2007;99:1782–92.
26. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA.
Validation of the Gail et al. model of breast cancer risk prediction
and implications for chemoprevention. J Natl Cancer Inst.
2001;93:358–66.
27. National Cancer Institute. Breast Cancer Risk Assessment Tool.
Last updated 16 May 2011. www.cancer.gov/bcrisktool. Acces-
sed 22 Mar 2015.
28. Matsuno RK, Costantino JP, Ziegler RG, et al. Projecting indi-
vidualized absolute invasive breast cancer risk in Asian and Pacific
Islander American women. J Natl Cancer Inst. 2011;103:951–61.
29. Freedman AN, Yu B, Gail MH, et al. Benefit/risk assessment for
breast cancer chemoprevention with raloxifene or tamoxifen for
women age 50 years or older. J Clin Oncol. 2011;29:2327–33.
30. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for
prevention of breast cancer: report of the National Surgical
Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst.
1998;90:1371–88.
31. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the
prevention of breast cancer: current status of the National Sur-
gical Adjuvant Breast and Bowel Project P-1 study. J Natl
Cancer Inst. 2005;97:1652–62.
32. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of
tamoxifen vs raloxifene on the risk of developing invasive breast
cancer and other disease outcomes: the NSABP Study of
Tamoxifen and Raloxifene (STAR) P-2 trial [published errata
appear in in JAMA. 2006;296(25):2926, and JAMA. 2007;298(9):
973]. JAMA. 2006;295:2727–41.
33. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the
National Surgical Adjuvant Breast and Bowel Project Study of
Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast
cancer. Cancer Prev Res (Phila). 2010;3:696–706.
34. Quante AS, Whittemore AS, Shriver T, Strauch K, Terry MB.
Breast cancer risk assessment across the risk continuum: genetic
and nongenetic risk factors contributing to differential model
performance. Breast Cancer Res. 2012;14:R144.
35. Amir E, Freedman OC, Seruga B, Evans DG. Assessing women
at high risk of breast cancer: a review of risk assessment models.
J Natl Cancer Inst. 2010;102:680–91.
36. Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for
breast-cancer prevention in postmenopausal women [published
erratum appears in N Engl J Med. 2011;365(14):1361]. N Engl J
Med. 2011;364:2381–91.
37. Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of
breast cancer in high-risk postmenopausal women (IBIS-II): an
3234 S. Pruthi et al.
international, double-blind, randomised placebo-controlled trial
[published erratum appears in Lancet. 2014;383(9922):1040].
Lancet. 2014;383:1041–8.
38. Diller L, Mauch P, Medeiros Nancarrow C, et al. A feasibility
study of tamoxifen chemoprevention in Hodgkin’s disease (HD)
survivors: 8551. J Clin Oncol. 2004;22:811s.
39. Cheung AM, Tile L, Cardew S, et al. Bone density and structure in
healthy postmenopausal women treated with exemestane for the
primary prevention of breast cancer: a nested substudy of the MAP.3
randomised controlled trial. Lancet Oncol. 2012;13:275–84.
40. Maunsell E, Goss PE, Chlebowski RT, et al. Quality of life in
MAP.3 (Mammary Prevention 3): a randomized, placebo-con-
trolled trial evaluating exemestane for prevention of breast
cancer. J Clin Oncol. 2014;32:1427–36.
41. Waters EA, McNeel TS, Stevens WM, Freedman AN. Use of
tamoxifen and raloxifene for breast cancer chemoprevention in
2010. Breast Cancer Res Treat. 2012;134:875–80.
42. Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluc-
tance toward tamoxifen use for breast cancer primary prevention.
Ann Surg Oncol. 2001;8:580–5.
43. Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM. Decision-
making about tamoxifen in women at high risk for breast cancer:
clinical and psychological factors. J Clin Oncol. 2004;22:4951–7.
44. Donnelly LS, Evans DG, Wiseman J, et al. Uptake of tamoxifen
in consecutive premenopausal women under surveillance in a
high-risk breast cancer clinic. Br J Cancer. 2014;110:1681–7.
45. Kaplan CP, Haas JS, Perez-Stable EJ, Des Jarlais G, Gregorich
SE. Factors affecting breast cancer risk reduction practices
among California physicians. Prev Med. 2005;41:7–15.
46. Jordan VC. Tamoxifen or raloxifene for breast cancer chemo-
prevention: a tale of two choices–point. Cancer Epidemiol
Biomarkers Prev. 2007;16:2207–9.
Chemoprevention for Breast Cancer 3235
